WhichPepsPeptides. Without the hype.

Epitalon

Tetrapeptide

Ageing biologytelomere research
Generic peptide vial illustrationEpitalon
Entity typePeptide
Evidence reviewed2026-09-18
Canonical recordEPITALON
Page updated2026-09-20
Evidence profileOlder indication-specific human evidence + modern in-vitro biology; longevity efficacy unproven
Human evidenceLimited
Regulatory statusNot FDA-approved
Choose your depthStart simple, then open the evidence or technical detail only if you need it.
Quick answerPlain languageEvidenceOutcomes and studiesStudiesPrimary recordsTechnicalMechanism, route and identifiers

In plain English

30-second evidence answer

What does the evidence mean in simple terms?

Epitalon has some older human research in narrow clinical settings and newer laboratory work on ageing-related biology. That does not establish that it extends human lifespan or works as a general anti-ageing treatment.

Still uncertain: Human lifespan extension, systemic anti-ageing benefit, general sleep benefit, long-term systemic safety or a validated longevity regimen.

New to terms such as “preclinical”, “randomized” or “investigational”? Use the plain-English glossary →

What does the evidence mean in simple terms? table
What is it?Tetrapeptide
Entity typePeptide
Research focusAgeing biology, telomere research, retinal research
Human evidenceOlder regional human evidence includes a 162-patient retinitis-pigmentosa study using a highly specific parabulbar route. Modern 2025 telomere findings are in cultured human cells, not a longevity trial. No large independent human lifespan trial was identified.
Regulatory statusNot FDA-approved; compounded-use safety information is insufficient.
Main limitationsHuman lifespan extension, systemic anti-ageing benefit, general sleep benefit, long-term systemic safety or a validated longevity regimen.
SafetyModern human safety and efficacy datasets are inadequate; FDA lists lack of safety information for compounded epitalon.
Evidence reviewed2026-09-18
i
Older regional human evidence includes a 162-patient retinitis-pigmentosa study using a highly specific parabulbar route. Modern 2025 telomere findings are in cultured human cells, not a longevity trial. No large independent human lifespan trial was identified.
Outcome-level evidence

Evidence is not one score.

Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.

How to read this →

Retinitis pigmentosa clinical response

Human evidence
Older regional human clinical evidence

Context: Patients with retinitis pigmentosa

Finding: There is disease-specific historical human exposure.

Regulatory / scope context: Study age, regional reporting and indication-specific route limit generalizability.

Verified 2026-09-18Primary source ↗

Human lifespan / anti-ageing benefit

Evidence gap
No robust modern human longevity efficacy established

Context: Healthy or ageing humans

Finding: Modern cell research can support mechanisms, not human lifespan claims.

Uncertainty / evidence gap: Human longevity claims are often mixed with Epithalamin/pineal-extract literature, which is not the same product.

Telomere-length effects

Preclinical evidence
In-vitro human-cell evidence

Context: Human cell lines

Finding: The peptide can alter telomere-related biology in vitro.

Uncertainty / evidence gap: Cell-line effects do not establish anti-ageing benefit and may have different implications in cancer cells.

Verified 2026-09-18Primary source ↗
Evidence rule: an outcome-specific evidence label is not a recommendation, a safety rating or an overall score for the compound.

Evidence synthesis

  • ✓There is disease-specific historical human exposure.
  • ✓Modern cell research can support mechanisms, not human lifespan claims.
  • ✓The peptide can alter telomere-related biology in vitro.

Important limitations

  • !Not a longevity trial and not systemic administration.
  • !Identity confusion and reliance on older regional studies are major limitations.
  • !No human in-vivo lifespan or disease-outcome endpoint.

Selected study & evidence records

Epitalon in retinitis pigmentosa

2002 · Older clinical study · n=162

The publication reported a positive clinical effect in approximately 90% of treated cases.

Study detail → Primary source ↗

Epitalon and telomere length in human cell lines

2025 · In-vitro human-cell study

Epitalon increased telomere length in several cultured human cell models and affected telomerase/ALT-associated biology.

Study detail → Primary source ↗

Safety and unknowns

Modern human safety and efficacy datasets are inadequate; FDA lists lack of safety information for compounded epitalon.

Systemic long-term human safety is not established; telomere/telomerase effects require careful interpretation, especially because cancer-cell models can respond differently.

Technical details

Mechanism / biologyInvestigated for gene-expression, telomerase/telomere and pineal/retinal biology.
Route / formulation boundaryDo not confuse Epitalon (tetrapeptide) with Epithalamin (pineal extract) when citing older literature.
Identity / data-quality noteSynthetic Epitalon must not be conflated with Epithalamin/pineal extract studies.
Study / label regimen evidenceVerified historical human retinal-study exposure added. A historical retinitis-pigmentosa study used 5.0 µg per eye by parabulbar injection for 10 consecutive days. That study exposure does not establish a general systemic or longevity dose.
Identifiers & alternate namesEpithalon

Source depth & provenance

WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.

2structured study records
3outcome records
6linked source records

How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.

Show supporting and discovery sources

Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.